Transition to Peginterferon Beta-1a (BIIB017) From Subcutaneous Interferon Therapy

NCT02234869 · clinicaltrials.gov ↗

PHASE4

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Due to a change in Biogen Idec's medical research plans.

Conditions

Relapsing Multiple Sclerosis

Interventions

DRUG: Interferon Beta
DRUG: BIIB017 (Peginterferon beta-1a)

Sponsor

Biogen